Company press releases
| Tid | Selskap | Tittel | Sektor | Kategori |
|---|---|---|---|---|
| 25 Mar 2022 08:47 CET |
ULTIMOVACS | Correction: Ultimovacs ASA: Annual Report 2021 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Mar 2022 07:50 CET |
ULTIMOVACS | Ultimovacs ASA: Notice of Annual General Meeting on 21 April 2022 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 25 Mar 2022 07:30 CET |
ULTIMOVACS | Ultimovacs ASA: Annual Report 2021 | 20103010 Biotechnology | Annual financial and audit Reports |
| 21 Mar 2022 08:00 CET |
ULTIMOVACS | Ultimovacs Hosting Key Opinion Leader Webinar on the Evolving Treatment Landscape of Melanoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Mar 2022 16:30 CET |
ULTIMOVACS | Ultimovacs to Present Preclinical Data on TET Platform at American Association for Cancer Research (AACR) 2022 Annual Meeting | 20103010 Biotechnology | Non-regulatory press releases |
| 17 Feb 2022 13:18 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 17 Feb 2022 08:00 CET |
ULTIMOVACS | Ultimovacs ASA: Fourth quarter 2021 result presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 Feb 2022 08:00 CET |
ULTIMOVACS | Ultimovacs ASA: Invitation to fourth quarter 2021 results webcast presentation | 20103010 Biotechnology | Non-regulatory press releases |
| 03 Feb 2022 08:00 CET |
ULTIMOVACS | Ultimovacs to Progress to Last Cohort in Phase I Prostate Cancer TENDU study | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Dec 2021 09:20 CET |
ULTIMOVACS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Dec 2021 08:00 CET |
ULTIMOVACS | First Patient Enrolled in Phase II DOVACC trial of UV1 in Advanced Ovarian Cancer | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 02 Dec 2021 19:00 CET |
ULTIMOVACS | Ultimovacs Granted Orphan Drug Designation by FDA for UV1 Cancer Vaccine in Metastatic Melanoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 02 Dec 2021 16:30 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 29 Nov 2021 20:15 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 25 Nov 2021 08:00 CET |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification for close associate | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 Nov 2021 08:00 CET |
ULTIMOVACS | Ultimovacs ASA: Third quarter 2021 result presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Nov 2021 14:00 CET |
ULTIMOVACS | Ultimovacs' SITC2021 Data Shows Enduring T cell Response for UV1 Combination in Melanoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Nov 2021 08:00 CET |
ULTIMOVACS | Ultimovacs ASA: Invitation to third quarter 2021 results presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 02 Nov 2021 10:57 CET |
ULTIMOVACS | Ultimovacs ASA - New share capital registered | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Oct 2021 07:37 CEST |
ULTIMOVACS | Ultimovacs ASA - Transactions by primary insiders and closely associated parties | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Oct 2021 00:06 CEST |
ULTIMOVACS | Ultimovacs ASA - Private placement of new shares successfully placed | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 Oct 2021 16:31 CEST |
ULTIMOVACS | Ultimovacs ASA - Contemplated private placement | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 Oct 2021 16:30 CEST |
ULTIMOVACS | Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC) | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Oct 2021 08:00 CEST |
ULTIMOVACS | Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Oct 2021 10:50 CEST |
ULTIMOVACS | Ultimovacs ASA: New share capital registered | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 13 Oct 2021 08:00 CEST |
ULTIMOVACS | Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 Oct 2021 18:34 CEST |
ULTIMOVACS | Ultimovacs ASA: Share capital increase related to exercise of options | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 08 Oct 2021 09:07 CEST |
ULTIMOVACS | Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances | 20103010 Biotechnology | Non-regulatory press releases |
| 04 Oct 2021 16:21 CEST |
ULTIMOVACS | Flagging av nedsalg under 5% eierskap | 20103010 Biotechnology | Flagging |
| 01 Oct 2021 12:30 CEST |
ULTIMOVACS | Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Aug 2021 08:00 CEST |
ULTIMOVACS | Ultimovacs ASA: Second quarter 2021 result presentation | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 12 Aug 2021 07:45 CEST |
ULTIMOVACS | Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 Aug 2021 17:00 CEST |
ULTIMOVACS | Ultimovacs ASA: Invitation to second quarter 2021 results webcast presentation | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 Aug 2021 08:00 CEST |
ULTIMOVACS | Ultimovacs announces first patient enrolled in Phase II FOCUS trial of UV1 in head-and-neck cancer | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 Jul 2021 21:30 CEST |
ULTIMOVACS | Ultimovacs' Announces Review Article Highlighting Telomerase-based Therapeutic Cancer Vaccines | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 04 Jun 2021 15:12 CEST |
ULTIMOVACS | Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 01 Jun 2021 08:31 CEST |
ULTIMOVACS | Ultimovacs Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 May 2021 17:08 CEST |
ULTIMOVACS | Ultimovacs ASA: Mandatory notification of trade by primary insider | 20103010 Biotechnology | Mandatory notification of trade primary insiders |